NY Times

FEBRUARY 9, 2022

It’s not clear whether three doses of the Pfizer-BioNTech vaccine will adequately protect young children. But the F.D.A. may authorize the first two doses anyway.

Vaccines 98

Vaccines Immunity Immunization 98

Pharmaceutical Technology

DECEMBER 30, 2024

Vidofludimus calcium is under clinical development by Immunic and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Immunity 40

Immunity Immunization 40

NY Times

JANUARY 27, 2021

Spain has suspended vaccinations in Madrid because of a shortfall of doses, as the European Union locks horns with the drugmaker AstraZeneca over vaccine delivery cuts.

Vaccines 98

Vaccines Immunity Immunization 98

NY Times

MAY 11, 2022

Antibody levels rose in the children who received it, suggesting the vaccine protects against infection. But the data were gathered before the arrival of Omicron.

Vaccines 98

Vaccines Immunity Immunization 98

ALiEM - Pharm Pearls

OCTOBER 21, 2024

A 5-year-old generally healthy fully immunized boy presented to the ED with worsening left ear redness, swelling, and tenderness that his family noticed the day before presentation. 2019 Aug;276(8):2199-2203. Epub 2019 May 11. His family had also recently noticed an abrasion over that ear. Klug TE, Holm N, Greve T, Ovesen T.

Medical Schools 169

Medical Schools Immunity Immunization 169

NY Times

DECEMBER 18, 2020

The Food and Drug Administration authorized a second coronavirus vaccine for emergency use, clearing the way for millions more Americans to be immunized next week.

Vaccines 104

Vaccines Immunization Immunity Nursing Homes 104

pharmaphorum

AUGUST 5, 2022

MiroBio was formed in 2019 to develop checkpoint agonist antibodies for autoimmune and inflammatory disorders that can be used to apply the “natural brakes” of the immune system. 7 integrin, with three candidates in early-stage clinical development.

Immunization 105

Immunization Immunity Drug Development 105

NY Times

MARCH 23, 2022

The company said the vaccine produced a strong immune response in children younger than 6, but proved only about 40 percent effective in preventing symptomatic Covid-19.

Vaccines 98

Vaccines Immunization Immunity 98

European Pharmaceutical Review

MAY 17, 2023

The viral therapy “aims to awaken the patient’s immune system and trigger a healing from within,” Dr Fueyo commented. After injection, patients that respond well develop inflammation inside the tumour, triggering an immune response that first kills the virus.” This makes it difficult to treat the cancer with immunotherapy.

Immunization 98

Immunization Immunity Chemotherapy 98

European Pharmaceutical Review

AUGUST 2, 2023

This is an additional ingredient designed to trigger a stronger immune response. The vaccine demonstrated a strong immune response in the trial. In a clinical trial, this vaccine was shown to faciliate a strong immune response against the Omicron BA.1 1 variant, in addition to the original 2020 strain.

Vaccines 98

Vaccines Immunity Immunization 98

European Pharmaceutical Review

JULY 13, 2023

The field of immunotherapy is constantly evolving with the ultimate goal to develop new treatments that help the body’s immune system fight cancer. Immune cells, such as T cells and natural killer (NK) cells, have the inherent ability to combat diseases, including cancer, but are often inhibited by the body’s own suppressive mechanisms.

Immunization 98

Immunization Immunity Hospitals 98

pharmaphorum

JANUARY 18, 2021

Quadri, formerly Merck’s head of medical and scientific affairs, immune oncology, has been charged with one count of theft of trade secrets and one count of unauthorised transmission of trade secrets, some relating to the multi-billion dollar cancer immunotherapy Keytruda (pembrolizumab).

Documentation 95

Documentation Immunity Immunization Pharmaceutical Companies 95

pharmaphorum

JUNE 16, 2022

The result isn’t a big surprise – Roche terminated two phase 3 trials of crenezumab in people with prodromal to mild sporadic Alzheimer’s in early 2019 after interim analyses found it would be futile to continue – but is another blow to the amyloid hypothesis.

Immunity 111

Immunity Immunization 111

Pharmacy Joe

SEPTEMBER 23, 2021

In this episode, I’ll discuss a possible syndrome that might herald vaccine-induced immune thrombotic thrombocytopenia. Episode 646: Does vaccine-induced immune thrombotic thrombocytopenia have a “pre-VITT syndrome” ? 4 of the patients experienced thrombosis and 7 did not. appeared first on Pharmacy Joe.

Immunity 40

Immunity Immunization Vaccines Inpatient 40

Express Pharma

OCTOBER 16, 2024

Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800 per cent increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. Bristol Myers Squibb formed a multi-year, $1.87

Vaccines 104

Vaccines Immunity Immunization Diabetes 104

European Pharmaceutical Review

JULY 12, 2022

By binding to both CD19, an antigen expressed on B-cells, and to the CD3 receptor on T-cells, TNB-486 activates and recruits T-cells to CD19-expressing tumours where they can elicit an immune response. “By The post AstraZeneca to acquire TeneoTwo and its blood-cancer therapeutic appeared first on European Pharmaceutical Review.

Immunity 98

Immunity Immunization Chemotherapy 98

European Pharmaceutical Review

MARCH 19, 2024

This pathway works in the innate immune system to sense cytosolic DNA by triggering a STING-dependent inflammatory response. In September 2019, IFM Due entered into an option and collaboration agreement with Novartis, who agreed to finance IFM Due’s research and development costs for the cGAS-STING programme.

Immunity 105

Immunity Immunization 105

pharmaphorum

APRIL 8, 2022

Once within the tumour, it stimulates receptors on immune cells to mount an attack on the cancer. It was launched as Intron A by Schering-Plough (now Merck & Co) in the 1980s before being discontinued by the company in 2019 based on evaluation of its clinical activity and the emergence of alternative therapies.

Immunity 105

Immunity Immunization 105

pharmaphorum

MARCH 11, 2021

VX-880 (formerly known as STx-02) derives from Vertex’ near $1 billion acquisition of Semma in 2019, and has started enrolling patients in a phase 1/2 study in the US. As this won’t be used in the initial phase 1/2 trial, patients will have to receive immunosuppressive drugs to dampen down the immune response.

Diabetes 98

Diabetes Immunity Immunization 98

pharmaphorum

JUNE 21, 2021

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot.

Vaccines 145

Vaccines Immunity Immunization 145

European Pharmaceutical Review

NOVEMBER 18, 2022

This is almost three times the 2019 market volume (5.8 billion), nearly three-and-a-half times the 2019 market value ($38 billion). Achieving Immunization Agenda 2030 goals. The document showed that in 2021, approximately 16 billion vaccine doses, worth $141 billion, were supplied across 47 vaccines and 94 manufacturers.

Vaccines 98

Vaccines Immunity Immunization Documentation 98

Express Pharma

FEBRUARY 22, 2024

Takeda entered into multiple cell therapy collaborations for the development of CAR-T therapies with organisations like Memorial Sloan Kettering Cancer Center (MSK), Noile-Immune Biotech, and Crescendo Biologics in 2019 to advance the company’s novel immuno-oncology portfolio.

Immunity 105

Immunity Immunization 105

ALiEM - Pharm Pearls

MARCH 29, 2023

2019 Mar; 2(3). Biondi EA, Lee B, Ralston SL, et al. Prevalence of Bacteremia and Bacterial Meningitis in Febrile Neonates and Infants in the Second Month of Life: A Systematic Review and Meta-analysis. JAMA Network Open. PMID: 30901044. Baker MD, Avner JR, Bell LM. Pediatrics. 1990;85(6):1040–1043.

Hospitals 360

Hospitals Documentation Inpatient Immunity 360

pharmaphorum

AUGUST 31, 2022

Kaiku’s DPPM platform has also attracted the attention of other big pharma groups, including Roche which has been working with the company since 2019 on personalised support modules for patients taking its PD-L1 inhibitor Tecentriq (atezolizumab).

Chemotherapy 116

Chemotherapy Immunity Immunization Hospitals 116

European Pharmaceutical Review

APRIL 25, 2023

This signals the cell to the immune system and so it targets and kills the myeloma cell. A promising treatment for myeloma DVD was first rolled out in 2019 after it was approved through the Cancer Drugs Fund.

Immunity 98

Immunity Immunization 98

European Pharmaceutical Review

JANUARY 26, 2024

It is a key component of human vaccines for shingles, malaria, coronavirus disease 2019 and others under development.” Bioengineering vaccine adjuvants The paper explained: “QS-21 is a potent vaccine adjuvant currently sourced by extraction from the Chilean soapbark tree. Martin et al. Martin et al.

Vaccines 98

Vaccines Compounding Immunity Immunization 98

The Thyroid Pharmacist

JUNE 30, 2023

However, low doses of this medication (hence, low dose naltrexone or LDN), have been found to modulate the immune system and have shown promise in improving cases of autoimmune disease. These include Crohn’s, MS, and Hashimoto’s, as well as other immune system-related conditions such as cancer and HIV/AIDS. Doses of 1.5-4.5

Compounding 98

Compounding Immunity Immunization Compounding Pharmacies 98

pharmaphorum

FEBRUARY 16, 2021

In 2019, Novartis also bought into the category via a $310 million takeover of IFM Therapeutics, which is developing NLRP3 drugs for atherosclerosis and non-alcoholic steatohepatitis (NASH), while UK startup NodThera raised $55 million last year for its own NLRP3 programme, eyeing NASH and diabetes.

Immunity 119

Immunity Immunization Diabetes 119

pharmaphorum

JUNE 27, 2022

Most people are able to shake off HBV infection over time, with drug therapy reducing vial levels to the extent that the immune system can keep the virus under control. The drug is designed to target viral DNA directly, which could give it a chance of targeting all traces of the virus in the body.

Immunity 124

Immunity Immunization 124

pharmaphorum

JUNE 3, 2021

Genmab has enlisted the help of Bolt Biotherapeutics to develop a new class of immune-boosting antibody conjugates for cancer in a deal that could be worth up to $880 million. “Creating bispecific ISACs turbo-charged with potent immune stimulants is a novel concept that has tremendous potential for patients,” he added.

Immunization 52

Immunization Immunity 52

pharmaphorum

JANUARY 7, 2022

That initial collaboration resulted in Sanofi licensing in a first drug candidate in 2019 for oncology and inflammatory diseases and – given the scale of the expanded agreement – the big pharma was clearly impressed by the relationship. It’s not the only one either.

Immunity 110

Immunity Immunization 110

Pharmaceutical Technology

APRIL 12, 2023

The latest shipment is based on an exclusive licence agreement signed in 2019 between Pharming and Novartis. Both genes are important for the body’s development and for the functioning of immune cells. Under its terms, Pharming has paid a $10m milestone payment to Novartis for the first commercial sale of Joenja.

Immunization 59

Immunization Immunity 59

pharmaphorum

APRIL 22, 2022

AP-013 started in June 2019 and was heavily impacted by the COVID-19 pandemic however, with too few patients recruited to allow it to assess the effect of Ampion on other measures such as joint function. .”

Immunity 111

Immunity Immunization 111

pharmaphorum

JULY 21, 2022

The London-based company was founded by venture capital firm Medicxi in 2019, but has now come out of stealth mode with financial backing of €18 million and a platform based on a ‘molecular clamp’ technology developed by researchers at the University of Queensland (UQ) in Australia.

Vaccines 105

Vaccines Immunity Immunization 105

pharmaphorum

SEPTEMBER 6, 2021

Some prosecutors are outraged that that it grants the Sackler family that owned the business immunity from any further lawsuits relating to their part in the opioid crisis.

Documentation 98

Documentation Immunity Immunization 98

pharmaphorum

MARCH 30, 2022

Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack among drugs targeting the immune checkpoint. SCLC is the most aggressive form of any lung cancer, accounting for around 15% of all cases, and is characterised by rapid progression and poor survival.

Chemotherapy 97

Chemotherapy Immunity Immunization 97

Pharmaceutical Technology

SEPTEMBER 21, 2022

In January 2019, the companies entered a collaboration agreement under which Pfizer agreed to use CytoReason’s technology for developing cell-based models of the immune system. With the latest development, the partnership would be worth up to $110m over the next five years.

Immunization 52

Immunization Immunity Drug Development 52